Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 4065382, 11 pages
http://dx.doi.org/10.1155/2016/4065382
Review Article

Histone Acetylation and Its Modifiers in the Pathogenesis of Diabetic Nephropathy

Department of Nephrology, The Second Hospital of Jilin University, Changchun 130041, China

Received 1 April 2016; Accepted 17 May 2016

Academic Editor: Konstantinos Papatheodorou

Copyright © 2016 Xiaoxia Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Reddy, J. Tak Park, and R. Natarajan, “Epigenetic modifications in the pathogenesis of diabetic nephropathy,” Seminars in Nephrology, vol. 33, no. 4, pp. 341–353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Matsushita, M. van der Velde, B. C. Astor et al., “Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis,” The Lancet, vol. 375, no. 9731, pp. 2073–2081, 2010. View at Publisher · View at Google Scholar
  4. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Yacoub and K. N. Campbell, “Inhibition of RAS in diabetic nephropathy,” International Journal of Nephrology and Renovascular Disease, vol. 8, pp. 29–40, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. O. Kolset, F. P. Reinholt, and T. Jenssen, “Diabetic nephropathy and extracellular matrix,” The Journal of Histochemistry and Cytochemistry, vol. 60, no. 12, pp. 976–986, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. G.-D. Sun, W.-P. Cui, Q.-Y. Guo, and L.-N. Miao, “Histone lysine methylation in diabetic nephropathy,” Journal of Diabetes Research, vol. 2014, Article ID 654148, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. K. Chokhandre, M. I. Mahmoud, T. Hakami, M. Jafer, and A. S. Inamdar, “Vitamin D & its analogues in type 2 diabetic nephropathy: a systematic review,” Journal of Diabetes and Metabolic Disorders, vol. 14, no. 1, article 186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Mezzano, C. Aros, A. Droguett et al., “NF-κB activation and overexpression of regulated genes in human diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 19, no. 10, pp. 2505–2512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Hasegawa, K. Nakano, M. Sawada et al., “Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy,” Kidney International, vol. 40, no. 6, pp. 1007–1012, 1991. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Lin, W. H. Yiu, H. J. Wu et al., “Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 86–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Singh, N. Alavi, A. K. Singh, and D. J. Leehey, “Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation,” Diabetes, vol. 48, no. 10, pp. 2066–2073, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Kato and R. Natarajan, “Diabetic nephropathy—emerging epigenetic mechanisms,” Nature Reviews Nephrology, vol. 10, no. 9, pp. 517–530, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kato and R. Natarajan, “MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets,” Annals of the New York Academy of Sciences, vol. 1353, no. 1, pp. 72–88, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Tonna, A. El-Osta, M. E. Cooper, and C. Tikellis, “Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms,” Nature Reviews: Nephrology, vol. 6, no. 6, pp. 332–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Brasacchio, J. Okabe, C. Tikellis et al., “Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail,” Diabetes, vol. 58, no. 5, pp. 1229–1236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Wang, X. Miao, Y. Liu et al., “Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 641979, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. H. Waterborg, “Dynamics of histone acetylation in vivo. A function for acetylation turnover?” Biochemistry and Cell Biology, vol. 80, no. 3, pp. 363–378, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Zhang, X. Dai, Y. Qi, Y. He, W. Du, and J.-J. Pang, “Histone deacetylases inhibitors in the treatment of retinal degenerative diseases: overview and perspectives,” Journal of Ophthalmology, vol. 2015, Article ID 250812, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Egger, G. Liang, A. Aparicio, and P. A. Jones, “Epigenetics in human disease and prospects for epigenetic therapy,” Nature, vol. 429, no. 6990, pp. 457–463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Lu, L. Wang, C. Yu, D. Yu, and G. Yu, “Histone acetylation modifiers in the pathogenesis of Alzheimer’s disease,” Frontiers in Cellular Neuroscience, vol. 9, article 226, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Reddy and R. Natarajan, “Epigenetics in diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 12, pp. 2182–2185, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. I. Campos and D. Reinberg, “Histones: annotating chromatin,” Annual Review of Genetics, vol. 43, pp. 559–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Mathiyalagan, S. T. Keating, X.-J. Du, and A. El-Osta, “Chromatin modifications remodel cardiac gene expression,” Cardiovascular Research, vol. 103, no. 1, pp. 7–16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. K. Chakrabarti, J. Francis, S. M. Ziesmann, J. C. Garmey, and R. G. Mirmira, “Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic β cells,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23617–23623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Mutskov, B. M. Raaka, G. Felsenfeld, and M. C. Gershengorn, “The human insulin gene displays transcriptionally active epigenetic marks in islet-derived mesenchymal precursor cells in the absence of insulin expression,” STEM CELLS, vol. 25, no. 12, pp. 3223–3233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Haumaitre, O. Lenoir, and R. Scharfmann, “Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors,” Molecular and Cellular Biology, vol. 28, no. 20, pp. 6373–6383, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Miao, I. G. Gonzalo, L. Lanting, and R. Natarajan, “In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions,” The Journal of Biological Chemistry, vol. 279, no. 17, pp. 18091–18097, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Reddy, S. Sahar, L. M. Villeneuve, L. Lanting, and R. Natarajan, “Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 387–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. G. Sayyed, A. B. Gaikwad, J. Lichtnekert et al., “Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1811–1817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Chen, J. Li, L. Jiao et al., “Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse,” Journal of Physiology, vol. 592, no. 3, pp. 505–521, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. De Marinis, M. Cai, P. Bompada et al., “Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney,” Kidney International, vol. 89, no. 2, pp. 342–353, 2016. View at Publisher · View at Google Scholar
  35. M. Kato, V. Dang, M. Wang et al., “TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy,” Science Signaling, vol. 6, no. 278, article ra43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Yuan, M. A. Reddy, G. Sun et al., “Involvement of p300/CBP and epigenetic histone acetylation in TGF-β1-mediated gene transcription in mesangial cells,” American Journal of Physiology—Renal Physiology, vol. 304, no. 5, pp. F601–F613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Das, N. Ghosh-Choudhury, B. Venkatesan, X. Li, L. Mahimainathan, and G. G. Choudhury, “Akt kinase targets association of CBP with SMAD 3 to regulate TGFβ-induced expression of plasminogen activator inhibitor-1,” Journal of Cellular Physiology, vol. 214, no. 2, pp. 513–527, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Reddy, P. Sumanth, L. Lanting et al., “Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice,” Kidney International, vol. 85, no. 2, pp. 362–373, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Wang, Y. Wang, M. Luo et al., “Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 1, pp. 34–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Tikoo, R. L. Meena, D. G. Kabra, and A. B. Gaikwad, “Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy,” British Journal of Pharmacology, vol. 153, no. 6, pp. 1225–1231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. V. M. Surse, J. Gupta, and K. Tikoo, “Esculetin induced changes in Mmp13 and Bmp6 gene expression and histone H3 modifications attenuate development of glomerulosclerosis in diabetic rats,” Journal of Molecular Endocrinology, vol. 46, no. 3, pp. 245–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Miao, Z. Chen, S. Genuth et al., “Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes,” Diabetes, vol. 63, no. 5, pp. 1748–1762, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. A. El-Osta, D. Brasacchio, D. Yao et al., “Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia,” The Journal of Experimental Medicine, vol. 205, no. 10, pp. 2409–2417, 2008. View at Google Scholar
  44. X. Y. Sun, H. J. Qin, Z. Zhang et al., “Valproate attenuates diabetic nephropathy through inhibition of endoplasmic reticulum stressinduced apoptosis,” Molecular Medicine Reports, vol. 13, no. 1, pp. 661–668, 2016. View at Google Scholar
  45. P. Y. Chuang, Y. Dai, R. Liu et al., “Alteration of forkhead box o (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus,” PLoS ONE, vol. 6, no. 8, article e23566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Shang, P. Gao, Z. Zhao et al., “3,5-Diiodo-l-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1832, no. 5, pp. 674–684, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Liu, Y. Zhong, X. Li et al., “Role of transcription factor acetylation in diabetic kidney disease,” Diabetes, vol. 63, no. 7, pp. 2440–2453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. Y.-G. Du, L.-P. Wang, J.-W. Qian, K.-N. Zhang, and K.-F. Chai, “Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats,” Chinese Journal of Integrative Medicine, 2015. View at Publisher · View at Google Scholar
  49. G. Chen, T. Wang, L. Uttarwar et al., “SREBP-1 is a novel mediator of TGFβ1 signaling in mesangial cells,” Journal of Molecular Cell Biology, vol. 6, no. 6, pp. 516–530, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Papadimitriou, K. C. Silva, E. B. M. I. Peixoto, C. M. Borges, J. M. L. de Faria, and J. B. L. de Faria, “Theobromine increases NAD+/Sirt-1 activity and protects the kidney under diabetic conditions,” American Journal of Physiology—Renal Physiology, vol. 308, no. 3, pp. F209–F225, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. C.-L. Lin, P.-H. Lee, Y.-C. Hsu et al., “MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction,” Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1698–1709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. B. R. Keppler and T. K. Archer, “Chromatin-modifying enzymes as therapeutic targets—part 1,” Expert Opinion on Therapeutic Targets, vol. 12, no. 10, pp. 1301–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. L. M. Villeneuve and R. Natarajan, “The role of epigenetics in the pathology of diabetic complications,” American Journal of Physiology—Renal Physiology, vol. 299, no. 1, pp. F14–F25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Kaur, S. Chen, X. Xin, J. Chiu, Z. A. Khan, and S. Chakrabarti, “Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300,” Diabetes, vol. 55, no. 11, pp. 3104–3111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Xu, J. Chiu, B. Feng, S. Chen, and S. Chakrabarti, “PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 24, no. 5, pp. 404–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Chen, B. Feng, B. George, R. Chakrabarti, M. Chen, and S. Chakrabarti, “Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells,” American Journal of Physiology—Endocrinology and Metabolism, vol. 298, no. 1, pp. E127–E137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Huang, D. Wan, J. Li, H. Chen, K. Huang, and L. Zheng, “Histone acetyltransferase PCAF regulates inflammatory molecules in the development of renal injury,” Epigenetics, vol. 10, no. 1, pp. 62–72, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Oike, H. Ogiwara, N. Amornwichet, T. Nakano, and T. Kohno, “Chromatin-regulating proteins as targets for cancer therapy,” Journal of Radiation Research, vol. 55, no. 4, pp. 613–628, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Balasubramanyam, R. A. Varier, M. Altaf et al., “Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription,” The Journal of Biological Chemistry, vol. 279, no. 49, pp. 51163–51171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Zammataro, M. A. Sortino, C. Parenti, R. W. Gereau, and S. Chiechio, “HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors,” Molecular Pain, vol. 10, no. 1, article 68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. S.-K. Kang, S.-H. Cha, and H.-G. Jeon, “Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells,” Stem Cells and Development, vol. 15, no. 2, pp. 165–174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Manzo, F. P. Tambaro, A. Mai, and L. Altucci, “Histone acetyltransferase inhibitors and preclinical studies,” Expert Opinion on Therapeutic Patents, vol. 19, no. 6, pp. 761–774, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Chiu, Z. A. Khan, H. Farhangkhoee, and S. Chakrabarti, “Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-κB,” Nutrition, vol. 25, no. 9, pp. 964–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. J.-M. Yun, I. Jialal, and S. Devaraj, “Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin,” The Journal of Nutritional Biochemistry, vol. 22, no. 5, pp. 450–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Ma, L. Phillips, Y. Wang et al., “Curcumin activates the p38MPAK-HSP25 pathway in vitro but fails to attenuate diabetic nephropathy in DBA2J mice despite urinary clearance documented by HPLC,” BMC Complementary and Alternative Medicine, vol. 10, article 67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Ogiwara, M. Sasaki, T. Mitachi et al., “Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression,” Cancer Discovery, vol. 6, no. 4, pp. 430–445, 2016. View at Publisher · View at Google Scholar
  67. Y. Yang, K. Liu, Y. Liang, Y. Chen, Y. Chen, and Y. Gong, “Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 3, pp. 2746–2754, 2015. View at Google Scholar · View at Scopus
  68. H. Noh, E. Y. Oh, J. Y. Seo et al., “Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury,” American Journal of Physiology—Renal Physiology, vol. 297, no. 3, pp. F729–F739, 2009. View at Google Scholar
  69. D. Y. Rhyu, Y. Yang, H. Ha et al., “Role of reactive oxygen species in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 667–675, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. X. Wang, J. Liu, J. Zhen et al., “Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy,” Kidney International, vol. 86, no. 4, pp. 712–725, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. Q. Wei and Z. Dong, “HDAC4 blocks autophagy to trigger podocyte injury: non-epigenetic action in diabetic nephropathy,” Kidney International, vol. 86, no. 4, pp. 666–668, 2014. View at Publisher · View at Google Scholar
  72. E. Seto and M. Yoshida, “Erasers of histone acetylation: the histone deacetylase enzymes,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 4, Article ID a018713, 2014. View at Google Scholar · View at Scopus
  73. K. Tikoo, D. N. Tripathi, D. G. Kabra, V. Sharma, and A. B. Gaikwad, “Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53,” FEBS Letters, vol. 581, no. 5, pp. 1071–1078, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Tikoo, K. Singh, D. Kabra, V. Sharma, and A. Gaikwad, “Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy,” Free Radical Research, vol. 42, no. 4, pp. 397–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Xu, L. Nie, Y.-G. Yin et al., “Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells,” Toxicology and Applied Pharmacology, vol. 259, no. 3, pp. 395–401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Y. Kim, J. H. Lim, H. H. Youn et al., “Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice,” Diabetologia, vol. 56, no. 1, pp. 204–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Bible, “Diabetic nephropathy: sirt1 attenuates diabetic albuminuria,” Nature Reviews Nephrology, vol. 9, no. 12, p. 696, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Hasegawa, S. Wakino, P. Simic et al., “Renal tubular sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes,” Nature Medicine, vol. 19, no. 11, pp. 1496–1504, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Kume, M. Haneda, K. Kanasaki et al., “SIRT1 inhibits transforming growth factor β-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 151–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Kume, M. Haneda, K. Kanasaki et al., “Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation,” Free Radical Biology and Medicine, vol. 40, no. 12, pp. 2175–2182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Li, F. Cai, Y. Yang et al., “Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-β1 pathway,” European Journal of Pharmacology, vol. 649, no. 1–3, pp. 382–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Kitada, A. Takeda, T. Nagai, H. Ito, K. Kanasaki, and D. Koya, “Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of sirt1 in diabetic wistar fatty (fa/fa) rats: a model of type 2 diabetes,” Experimental Diabetes Research, vol. 2011, Article ID 908185, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Huang, J. Huang, X. Xie et al., “Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells,” Free Radical Biology and Medicine, vol. 65, pp. 528–540, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Huang, C. Chen, J. Hao et al., “Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells,” Molecular and Cellular Endocrinology, vol. 399, pp. 178–189, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Kume, M. Kitada, K. Kanasaki, H. Maegawa, and D. Koya, “Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy,” Archives of Pharmacal Research, vol. 36, no. 2, pp. 230–236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Polak-Jonkisz, K. Laszki-Szczachor, L. Rehan, W. Pilecki, H. Filipowski, and M. Sobieszczańska, “Nephroprotective action of sirtuin 1 (SIRT1),” Journal of Physiology and Biochemistry, vol. 69, no. 4, pp. 957–961, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. Y.-J. Dong, N. Liu, Z. Xiao et al., “Renal protective effect of sirtuin 1,” Journal of Diabetes Research, vol. 2014, Article ID 843786, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. F. F. Wagner, U. M. Wesmall yi, M. C. Lewis, and E. B. Holson, “Small molecule inhibitors of zinc-dependent histone deacetylases,” Neurotherapeutics, vol. 10, no. 4, pp. 589–604, 2013. View at Google Scholar
  89. H. B. Lee, H. Noh, J. Y. Seo, M. R. Yu, and H. Ha, “Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy,” Kidney International Supplement, no. 106, pp. S61–S66, 2007. View at Google Scholar
  90. M. G. Riggs, R. G. Whittaker, J. R. Neumann, and V. M. Ingram, “n-Butyrate causes histone modification in HeLa and friend erythroleukaemia cells,” Nature, vol. 268, no. 5619, pp. 462–464, 1977. View at Publisher · View at Google Scholar · View at Scopus
  91. E. P. M. Candido, R. Reeves, and J. R. Davie, “Sodium butyrate inhibits histone deacetylation in cultured cells,” Cell, vol. 14, no. 1, pp. 105–113, 1978. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Khan and G. Jena, “Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-β1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats,” Food and Chemical Toxicology, vol. 73, pp. 127–139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. V. M. Richon, S. Emiliani, E. Verdin et al., “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 3003–3007, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Advani, Q. Huang, K. Thai et al., “Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism,” The American Journal of Pathology, vol. 178, no. 5, pp. 2205–2214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. R. E. Gilbert, Q. Huang, K. Thai et al., “Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor,” Kidney International, vol. 79, no. 12, pp. 1312–1321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Yoshikawa, K. Hishikawa, T. Marumo, and T. Fujita, “Inhibition of histone deacetylase activity suppresses epithelial-to- mesenchymal transition induced by TGF-β1 in human renal epithelial cells,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 58–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Khan, G. Jena, and K. Tikoo, “Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat,” Experimental and Molecular Pathology, vol. 98, no. 2, pp. 230–239, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Khan, G. Jena, K. Tikoo, and V. Kumar, “Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-κB/iNOS signaling in diabetic rat,” Biochimie, vol. 110, pp. 1–16, 2015. View at Publisher · View at Google Scholar · View at Scopus